Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Genital Diseases 1Carcinoma, Endometrioid 1

Interventions

Specimen Handling 3Nivolumab 3olaparib 2durvalumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2temsirolimus 1serabelisib 1sapanisertib 1rucaparib 1copanlisib 1ceralasertib 1cediranib 1capivasertib 1cabozantinib 1Paclitaxel 1Immunoglobulin G 1Fluid Therapy 1Disulfides 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Endometrioid × serabelisib × Clear all
NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡